65156-94-7

Basic information

• Product Name: 5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE
• Synonyms: 5-Chloro-4-azaindole,5-chloro-1H-pyrrolo[3,2-b]pyridine;1H-Pyrrolo[3,2-b]pyridine, 5-chloro-;5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE;5-Chloro-4-azaindole
• CAS NO: 65156-94-7
• Molecular Formula: C₇H₅ClN₂
• Molecular Weight: 152.58
• Product Categories: Azaindoles
• Mol File: 65156-94-7.mol

Chemical Properties

• Boiling Point: 304.9 °C at 760 mmHg
• Flash Point: 166.8 °C
• Appearance: /
• Density: 1.425 g/cm³
• Vapor Pressure: 0.00153mmHg at 25°C
• Refractive Index: 1.703
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 13.75±0.40(Predicted)
• CAS DataBase Reference: 5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE(65156-94-7)
• EPA Substance Registry System: 5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE(65156-94-7)

Safety Data

• Hazard Codes: Xi
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 65156-94-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE is used as a building block for the synthesis of biologically active molecules, contributing to the development of potential drug candidates. Its unique structure and reactivity make it a valuable intermediate in the creation of new pharmaceuticals.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE is utilized for its potential to contribute to the discovery and development of novel therapeutic agents. Its unique properties and reactivity allow researchers to explore its potential in creating new compounds with specific biological activities.
Used in Agrochemical Development:
5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE also finds application in the agrochemical industry, where it is used as a starting material for the synthesis of new agrochemicals. Its potential to form various biologically active molecules makes it a valuable component in the development of innovative products for agricultural use.
Used in Drug Discovery:
As a compound with unique properties, 5-CHLORO-1H-PYRROLO[3,2-B] PYRIDINE is employed in drug discovery processes to identify and develop new therapeutic agents. Its potential applications in creating novel pharmaceuticals make it an important target for research and development in the pharmaceutical industry.

InChI:InChI=1/C7H5ClN2/c8-7-2-1-5-6(10-7)3-4-9-5/h1-4,9H

Upstream product

• 123846-69-5 (6-Chloro-3-nitro-pyridin-2-yl)acetonitrile 
• 1612287-47-4 6-chloro-2-((trimethylsilyl)ethynyl)pyridin-3-amine 
• 1050501-88-6 2-bromo-6-chloro-pyridin-3-amine 
• 400777-06-2 6-chloro-2-iodopyridin-3-amine 
• 1420070-26-3 6-chloro-2-[(E)-2-ethoxyvinyl]pyridin-3-amine 
• 209287-23-0 pyrrolo[3,2-b]pyrid-5-one 
• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 1116138-21-6 5-chloro-1-tosyl-1H-pyrrolo[3,2-b]pyridine 

Downstream Products

• 209286-85-1 5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine 
• 1000343-73-6 3-bromo-5-methyl-1H-pyrrolo[3,2-b]pyridine 
• 4943-67-3 ?5-methyl-1H-pyrrolo[3,2-b]pyridine 
• 1612287-80-5 N,N,3-trimethyl-4-(1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl)benzenesulfonamide 
• 1116136-63-0 5-chloro-3-nitro-1H-pyrrolo[3,2-b]pyridine 
• 1116136-64-1 5-chloro-1H-pyrrolo[3,2-b]pyridin-3-amine 

Relevant articles and documents

PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS

The invention relates to compounds or pharmaceutically acceptable salts thereof of formula (I): (I) wherein R1, R2, R3, R4, R4' and R5 are as defined in the description and claims; and comp

6-(MORPHOLIN-4-YL)-PYRIDIN-2-YL-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS M-TOR INHIBITORS

The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

New bicyclic compounds as crac channel modulators

The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

New CRTh2 antagonists

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

NEW CRTH2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: Exploration of 5-6 fused rings as alternative S1 moieties

A series of cis-1,2-diaminocyclohexane derivatives were synthesized with the aim of optimizing previously disclosed factor Xa (fXa) inhibitors. The exploration of 5-6 fused rings as alternative S1 moieties resulted in two compounds which demonstrated improved solubility and reduced food effect compared to the clinical candidate, compound A. Herein, we describe the synthesis and structure-activity relationship (SAR), together with the physicochemical properties and pharmacokinetic (PK) profiles of some prospective compounds.

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Pharmaceutically active 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines

Compounds of the formula STR1 wherein one of A, B, D and E is N and the remaining three atoms are C; R1 and R2 are independently selected from hydrogen and C1 to C6 alkyl; and R3, R4, R5 and R6 are independently selected from hydrogen, halogen, hydroxy, C1 -C6 alkyl, C1 -C8 alkoxy, phenyl-C1 -C6 alkoxy, phenoxy --NR7 R8 wherein R7 and R8 are independently selected from hydrogen, C1 -C8 alkyl, C1 -C6 alkanoyl and COOR9 wherein R9 is hydrogen or C1 -C6 alkyl, cyano, COOR10 wherein R10 is hydrogen or C1 -C6 alkyl, and CONR11 R12 where R10 and R11 are independently selected from hydrogen and C1 -C6 alkyl, and the pharmaceutically acceptable salts thereof. The compounds are useful psychotherapeutics and may be used in treating obesity, depression and disorders wherein aggression is a symptom.